CA 125 kinetics: A cost-effective clinical tool to evaluate clinical trial outcomes in the 1990s
- 30 April 1996
- journal article
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 174 (4) , 1241-1254
- https://doi.org/10.1016/s0002-9378(96)70667-1
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Meta-analysis Comparing Cisplatin Total Dose Intensity and SurvivalGynecologic Oncology, 1995
- Serum Half-Life of CA 125 during Early Chemotherapy as an Independent Prognostic Variable for Patients with Advanced Epithelial Ovarian Cancer: Results of a Multicentric Italian StudyGynecologic Oncology, 1995
- Salvage Therapy for Recurrent and Refractory Ovarian Cancer with High-Dose Chemotherapy and Autologous Bone Marrow Support: A Gynecologic Oncology Group Pilot StudyGynecologic Oncology, 1994
- CA 125 serum levels in the early post-operative period do not reflect tumour reduction obtained by cytoreductive surgeryEuropean Journal Of Cancer, 1993
- Serum CA125 regression in epithelial ovarian cancer: Correlation with reassessment findings and survivalGynecologic Oncology, 1992
- Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancerThe Lancet, 1992
- CA 125 regression: A model for epithelial ovarian cancer responseAmerican Journal of Obstetrics and Gynecology, 1991
- Ovarian cancer: The prognostic value of the serum half-life of CA125 during induction chemotherapyGynecologic Oncology, 1988
- Analysis of clinical trials in gynecologic cancer—Timing and interpretationGynecologic Oncology, 1986
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983